Jefferies Analyst Predicts FDA Emergency Use Nod For Veru's New COVID-19 Therapy In One MonthBenzinga • 07/07/22
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 PatientsGlobeNewsWire • 07/06/22
Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDSGlobeNewsWire • 06/07/22
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual MeetingGlobeNewsWire • 06/06/22
Veru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7GlobeNewsWire • 05/31/22
Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 PatientsGlobeNewsWire • 05/18/22
Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022GlobeNewsWire • 05/17/22
5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain ElevatedBenzinga • 05/16/22
Veru Inc.'s (VERU) CEO Mitchell Steiner on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use AuthorizationGlobeNewsWire • 05/12/22
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 PatientsGlobeNewsWire • 05/11/22